Direct comparison
NCD 310.1 vs TCET vs RAPID vs CED
Compare Medicare's four coverage mechanisms for clinical trials and breakthrough devices: NCD 310.1, TCET, RAPID, and CED, side by side.
Side-by-side comparison
| Dimension | NCD 310.1 | TCET | RAPID | CED |
|---|---|---|---|---|
| What it governs | Whether Medicare pays routine patient-care costs for a beneficiary in a qualifying clinical trial | Whether a new FDA Breakthrough Device gets time-limited national coverage quickly | How fast CMS can propose/finalize a national coverage determination for an eligible Breakthrough Device | Whether continued coverage of a specific item/service is conditioned on ongoing evidence generation |
| Legal / regulatory basis | CMS National Coverage Determination 310.1, effective July 9, 2007 | CMS final procedural notice, Aug. 7, 2024 (Federal Register 2024-17603) | Joint CMS/FDA announcement, April 23, 2026; final Federal Register notice still pending as of mid-2026 | Applied within an NCD under Social Security Act Sec. 1862(a)(1)(A); CMS guidance updated Aug. 7, 2024 |
| What actually gets paid | Routine costs (visits, imaging, labs) and complication treatment -- not the investigational item itself | The device/technology itself, under national coverage, while evidence accumulates | Sets up the NCD that then determines what is paid -- RAPID accelerates the process, not the payment terms | The item/service itself, conditioned on registry submission or study enrollment continuing |
| Eligibility scope | Any trial meeting 3 threshold criteria plus 1 deeming criterion (NIH/CDC/AHRQ/CMS/DOD/VA funding, active IND, or IND-exempt) or a completed qualifying-trial checklist | FDA Breakthrough Device designation; existing Medicare benefit category (excludes digital therapeutics); capped at 5 devices/year | FDA Breakthrough Device designation; Class II devices need FDA TAP participation, Class III eligible regardless; device must have an active IDE study enrolling Medicare beneficiaries | Applies per-NCD, whenever CMS judges the evidence promising but not yet sufficient for unconditional coverage |
| How it is entered | Automatic once deeming criteria are met; billing requires the trial’s NCT number plus condition code 30 on claims | Manufacturer self-nomination (up to 12 months pre-authorization) or non-binding letter of intent (18-24 months pre-authorization), via quarterly review cycles | CMS can issue a proposed NCD the same day as FDA market authorization, no separate post-authorization coverage request needed | Built into a specific NCD through the standard NCD/reconsideration process, not a separate application track |
| Timeline to a coverage decision | N/A -- ongoing billing policy, not a per-product review | CMS targets finalizing the NCD within roughly 6 months of FDA market authorization | Target: national coverage finalized roughly 60-90 days after FDA market authorization | N/A -- tied to whatever NCD it is attached to |
| Duration once granted | Permanent policy; applies to each qualifying trial for its duration | Time-limited national coverage, up to 5 years | Set by the resulting NCD; RAPID itself does not impose the fixed sunset TCET does | Runs until CMS reconsiders the NCD -- historically anywhere from about 1 to 16+ years depending on the technology |
| Status as of mid-2026 | Long-standing, fully active since 2007 | Paused for new candidate devices since April 2026 as CMS shifts focus to RAPID; existing participants not displaced | Announced; final Federal Register notice setting the operational effective date not yet published | Active, ongoing mechanism; roughly two dozen CED-based NCDs issued 2005-2022 across a handful of therapeutic areas |
| Administrative burden for research offices | Moderate -- confirm qualifying-trial status, ensure correct NCT number and condition code 30 on every claim | Low for research administrators directly -- mainly a manufacturer/CMS nomination process to track for eligibility | High for IDE-study sites -- Medicare-beneficiary enrollment and pre-agreed clinical outcomes must be built into the protocol from the start | High and ongoing -- registry submission or study-enrollment documentation required for as long as the condition applies |
| Who it is really for | Any clinical trial’s routine-cost billing -- drugs, biologics, and devices alike | Sponsors of FDA Breakthrough Devices seeking accelerated, time-limited national coverage (new candidates currently paused) | Sponsors and IDE-study sites for FDA Breakthrough Devices seeking the fastest current path to national coverage | Any institution providing an item/service where CMS attached an evidence-development condition (e.g., TAVR, formerly amyloid PET) |
Common questions
FAQ
Can NCD 310.1, TCET, RAPID, and CED apply to the same study at once?+
Yes, in principle. A single Breakthrough Device IDE study could have its routine care costs governed by NCD 310.1 if structured as a qualifying trial, its path to national coverage run through RAPID (or TCET, for an earlier device), and the resulting NCD still carry a CED registry or study-participation requirement once coverage begins. They answer independent questions and are not mutually exclusive.
Is TCET still accepting new devices?+
No. CMS paused TCET for new candidate devices as of the April 2026 RAPID announcement while it stands up RAPID. Devices already participating in TCET are not described as being displaced, but the pathway is not accepting new nominations.
Is RAPID fully operational yet?+
Not as of this writing. CMS’s own description of the process requires a proposed procedural notice in the Federal Register with a 60-day public comment period before a final notice sets RAPID’s operational effective date. Research administrators should confirm against that final notice rather than treating the April 2026 announcement alone as making RAPID live.
Does NCD 310.1 apply to devices, or only drugs?+
NCD 310.1 applies to qualifying clinical trials generally -- drug, biologic, and device trials alike -- as long as the trial meets its threshold and deeming criteria. It is the only one of the four mechanisms compared here that is not device-specific.
If a device gets a RAPID-track national coverage determination, does that avoid a CED requirement?+
Not necessarily. RAPID changes how quickly an NCD can be proposed and finalized; it does not change whether CMS decides that NCD should carry a Coverage with Evidence Development condition. The two are independent decisions CMS can combine.
Going deeper
